VolitionRx Limited (VNRX) 株式分析

企業概要

VolitionRx Limited is a multi-national epigenetics enterprise dedicated to developing and deploying advanced blood tests designed to detect and monitor a spectrum of cancers and diseases associated with NETosis across the United States, Europe, and Asia. The company operates within the Healthcare sector, specifically focusing on the Medical Devices industry, a classification that underscores its specialization in diagnostic equipment and analytical technologies rather than pharmaceutical manufacturing or service provision. This business model targets a critical need for non-invasive screening solutions, such as Nu.Q Vet for canine cancer detection and Nu.Q Nets for human applications, positioning the firm at the intersection of veterinary innovation and human health diagnostics. As of the latest data, the company maintains a market capitalization of $27.72M and generates $1.73M in annual revenue, while its employee count is not disclosed in public records. These financial figures indicate that VolitionRx is currently a micro-cap entity with a relatively small market footprint, suggesting that its valuation is driven primarily by growth potential and intellectual property assets rather than established operational scale or massive revenue streams typical of large-cap peers.

財務健全性

The company reported $1.73M in revenue over the trailing twelve months, yet recorded a net income of $-23,357,028 and an EBITDA of $-20,754,864, revealing a profound disconnect between top-line sales and bottom-line profitability. This significant negative gap indicates that the cost structure is heavily weighted toward research and development expenses, operational overhead, or strategic investments that currently exceed all generated revenue. Free cash flow stands at $-8,515,099, which signifies that the company is burning through cash reserves to fund its operations and expansion, thereby limiting its immediate financial flexibility and reliance on external capital markets. Margin analysis reveals a gross margin of 100.0%, suggesting that the cost of goods sold is negligible or that revenue is recognized before direct product costs in this specific reporting period, while the operating margin of -1077.9% and profit margin of 0.0% highlight severe operational inefficiencies or substantial one-time losses relative to sales volume. On the balance sheet, VolitionRx holds $1.12M in cash against $11.46M in debt, creating a net cash deficit, and the debt-to-equity ratio is not available due to the negative equity position. This leverage structure is inherently risky, as the company must service significant debt obligations without sufficient liquid assets to cover them in the short term. Furthermore, the current ratio is 0.17, a figure well below the standard threshold of 1.0, indicating that the company possesses only about 17 cents of current assets for every dollar of current liabilities and faces potential short-term liquidity constraints. Return on Equity is not available given the negative shareholder equity, while Return on Assets is -166.7%, demonstrating that the asset base is generating negative returns and that management effectiveness in deploying capital to generate profit is currently failing.

バリュエーション評価

Valuation metrics present a complex picture for VolitionRx, with a trailing twelve-month P/E ratio of N/A due to the net loss, contrasted by a forward P/E of 0.73 which implies a market expectation of future profitability or a specific accounting treatment for forward estimates. The price-to-book ratio is -0.55, a negative figure that typically indicates the market values the company below its book value or reflects significant liabilities, suggesting the stock is priced at a deep discount relative to its accounting net assets. The price-to-sales ratio of 16.05 suggests that investors are willing to pay a premium of over 16 times annual revenue for every dollar of sales, a metric often seen in high-growth biotech firms where revenue quality and future scalability are valued over current earnings. Additionally, the EV/EBITDA stands at -1.77, further confirming that traditional earnings-based valuation models are less applicable and that the market is pricing in significant turnaround potential or future cash flow generation. The stock trades between a 52-week high of $0.94 and a 52-week low of $0.17, meaning the current trading price sits somewhere within this compressed range, reflecting the high volatility typical of small-cap healthcare stocks. The beta of 1.33 indicates that the stock's price volatility is 33% higher than the broader market, signaling that price movements will likely be more pronounced than the S&P 500 during periods of market stress or rally.

Growth & Income

VolitionRx has demonstrated robust top-line expansion with a revenue growth rate of 133.2% year-over-year, while earnings growth is N/A as the company remains unprofitable. This divergence implies that the company is successfully scaling its sales pipeline and market penetration, but profitability has not yet materialized to match the rapid revenue acceleration. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flow is being retained and reinvested into research and development to fuel future growth rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by aggressive expansion and zero current income distribution, relying entirely on future operational success to convert losses into sustainable earnings. The absence of a dividend aligns with the company's stage of development, where capital preservation for R&D is prioritized over shareholder returns.